Table 2: Trials Investigating the Effect of IV Iron in Chronic Stable Heart Failure.
| FAIR-HF2 | IRON-MAN | HEART-FID | |
|---|---|---|---|
| NCT number | NCT03036462 | NCT02642562 | NCT03037931 |
| Patient population | HFrEF >12 months + iron deficiency | HFrEF + iron deficiency | HFrEF + iron deficiency |
| Design | Multicentre RCT | Multicentre RCT | Multicentre RCT |
| Randomisation | 1:1 FCM versus placebo | 1:1 iron (III) isomaltoside versus placebo | 1:1 FCM versus placebo |
| Sample size | 1,200 | 1,300 | 3,014 |
| Duration trial | >12 months | >2.5 year | 12 months |
| Primary endpoint | HF hospitalisation and CV mortality | HF hospitalisation and CV mortality | HF hospitalisation and CV mortality |
| Trial status | Actively recruiting | Active, not recruiting | Recruiting |
CV = cardiovascular; FCM = ferric carboxymaltose; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; RCT = randomised controlled trial.